The U.S. Food and Drug Administration has granted fast-track designation to a new therapy for aggressive ovarian, fallopian tube, and peritoneal cancer, according to Targeted Oncology. Developed by the Chinese firm RemeGen, RC88 is designed for patients with treatment-resistant cancers and poor prognoses. Phase 2 clinical trials are slated to begin soon.
Rick Good spent ten years in the newspaper business, including with The News & Observer (Raleigh, NC) and The Greenville News (Greenville, SC). He co-wrote, with Melinda Coleman, Rutledge to Riley: Governors of South Carolina, 1776–Present (Published by The Greenville News), and is the author of Mind Games Trivia #1 (Amazon). He has recently spent 15 years creating original trivia content through Sounds Good Mobile Entertainment and continues that with his new company, SGME Software. He edits The Smart Reader’s money, real estate, and business coverage.
